Over 90 percent of drugs that show promise in early-phase clinical trials fail to reach the … Why Many Drugs Fail Despite Positive Trial ResultsRead more
Regulatory Compliance
Focused on FDA, PhRMA, MLR reviews, and legal guardrails for marketers.
Why Drugs Fail After Phase I in the U.S. Market
In the United States, roughly 12 percent of drugs that enter clinical testing ultimately receive approval … Why Drugs Fail After Phase I in the U.S. MarketRead more
Why Regulatory Delays Are Only Part of the U.S. Clinical Trial Problem
When a development program misses projected timelines, the explanation often centers on regulatory review. FDA feedback … Why Regulatory Delays Are Only Part of the U.S. Clinical Trial ProblemRead more
Why U.S. Clinical Trial Timelines Keep Getting Longer
The average time required to bring a new medicine from discovery to approval in the United … Why U.S. Clinical Trial Timelines Keep Getting LongerRead more
How Poor Trial Design Increases Drug Development Costs
In pharmaceutical development, clinical trials serve as the backbone of bringing a new therapy from concept … How Poor Trial Design Increases Drug Development CostsRead more
How Pharma Marketing Impacts Clinical Trial Success
In the United States, nearly 80 percent of clinical trials fail to meet their original enrollment … How Pharma Marketing Impacts Clinical Trial SuccessRead more
Why So Many Pharma Companies Get Stuck in Phase I Clinical Trials
In the United States, drug development rarely collapses at the finish line. It slows, fragments, and … Why So Many Pharma Companies Get Stuck in Phase I Clinical TrialsRead more
AI-Based Content Scoring for Medical Accuracy: Ensuring Reliable Communication in U.S. Pharma
Maintaining medical accuracy in pharmaceutical content is critical for both regulatory compliance and physician trust. With … AI-Based Content Scoring for Medical Accuracy: Ensuring Reliable Communication in U.S. PharmaRead more
Real-Time Brand Health Tracking for Pharma Leaders
The U.S. pharmaceutical landscape is evolving at an unprecedented pace. Clinicians, payers, and patients form perceptions … Real-Time Brand Health Tracking for Pharma LeadersRead more
AI-Driven Lead Enrichment for Life-Science Marketers |AI lead enrichment
In 2024, the U.S. pharmaceutical market surpassed $635 billion, with new drug launches and specialty therapies … AI-Driven Lead Enrichment for Life-Science Marketers |AI lead enrichmentRead more